Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
  • C07D487/16—Peri-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/4035—Isoindoles, e.g. phthalimide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
  • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0815—Tripeptides with the first amino acid being basic
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention relates to compounds useful as inhibitors of HCV protease.
• the invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
• HCV Hepatitis C virus
• HCV is a positive-stranded RNA virus whose genome encodes a polyprotein of approximately 3000 amino acids. This precursor protein is processed into at least 10 viral structural and nonstructural proteins: C, El, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B (Blight, K. J., et al., Antiviral Ther. 3, Suppl. 3: 71-81, 1998). HCV nonstructural (NS) proteins are derived by proteolytic cleavage of the polyprotein and are presumed to provide the essential catalytic machinery for viral replication.
• NS nonstructural
• NS3 is an approximately 68 Kda protein, and has both an N-terminal serine protease domain and an RNA-dependent ATPase domain at its C-terminus. It has been shown that the NS4A protein serves as a co-factor for the serine protease activity of NS3. NS3 functions as a proteolytic enzyme that cleaves sites liberating other nonstructural proteins necessary for HCV replication and is a viable therapeutic target for antiviral chemotherapy.
• R 1 , R 1 , R 2a , R 3 , R 4 and R z are as defined herein.
• HCV diseases, disorders, or conditions include those described herein.
• Compounds provided by this invention are also useful for the study of HCV protease in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by HCV protease; and the comparative evaluation of new HCV protease inhibitors.
• Figure 1 depicts a mass spectroscopic analysis of HCV NS3/4A wild-type protease in the presence of test compound 1-1.
• Figure 2 depicts a mass spectroscopic analysis of HCV NS3/4A wild-type protease in the presence of test compound 1-25.
• Figure 3 depicts a mass spectroscopic analysis of HCV NS3/4A protease.
• Figure 4 depicts a mass spectroscopic analysis of HCV NS3/4A mutant D 168V protease in the presence of test compound 1-11.
• Figure 5 depicts a mass spectroscopic analysis of HCV NS3/4A mutant A156S protease in the presence of test compound 1-11.
• Figure 6 depicts a mass spectroscopic analysis of HCV NS3/4A mutant R155K protease in the presence of test compound 1-11.
• Figure 7 depicts a mass spectroscopic analysis of HCV NS3/4A mutant A156T protease in the presence of test compound 1-11.
• Figure 8 depicts that the NS3 internal self-cleavage products are inhibited by treatement of replicon cells with Compound 1-47 for 16 hours.
• Figure 9 depicts an irreversible covalent inhibitor (compound 1-11) of NS3 protease demonstrates prolonged inhibition of NS3 protease activity in the wild-type replicon cells, as measured by self-cleavage, after the compounds are removed.
• Figure 10 depicts an irreversible covalent inhibitor (compound 1-25) of NS3 protease demonstrate prolonged inhibition of NS3 protease activity in the wild-type replicon cells, as measured by self-cleavage, after the compounds are removed.
• the present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein:
• R and R are independently hydrogen or optionally substituted C 1-6 aliphatic, or R and R are taken together to form an optionally substituted 3-7 membered carbocyclic ring;
• R 2a is -OH or -NHSO 2 R 2 ;
• R is -N(R) 2 or an optionally substituted group selected from C 3 _ 7 cycloalkyl, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen, optionally substituted C 1-6 aliphatic, or: two R on the same nitrogen atom are taken together with the nitrogen to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 3 is a warhead group, or:
• R and R are taken together with their intervening atoms to form an optionally substituted saturated or unsaturated 12-18 membered ring having 2-6 heteroatoms independently selected from nitrogen oxygen, or sulfur, wherein the ring formed thereby comprises a warhead group; or
• R 3 and a ring formed by R 1 and R 1 ' are taken together with their intervening atoms to form an optionally substituted saturated or unsaturated 12-18 membered ring having 2-6 heteroatoms independently selected from nitrogen oxygen, or sulfur, wherein the ring formed thereby comprises a warhead group;
• R 4 is H, -NHC(O)R 5 , -NHC(O)OR 6 , or a natural or unnatural amino acid side-chain group;
• each R 5 is independently -N(R) 2 or an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• R 6 is an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• R 7 is an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and
• R z is ; or R and R z are taken together with their intervening atoms to form an optionally substituted, saturated or unsaturated 16-22 membered ring having 2-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each occurrence of R y is independently selected from halogen, -OR°, -CN, -NO 2 , -N(R°) 2 , or optionally substituted C 1-4 aliphatic; and m is an integer from 0 to 4, inclusive; s is an integer from 0 to 4, inclusive; t is an integer from 0 to 4, inclusive; wherein the sum of s and t is non-zero.
• aliphatic or "aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
• aliphatic groups contain 1-6 aliphatic carbon atoms.
• aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
• cycloaliphatic (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C 3 -C 6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
• Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
• bridged bicyclic refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge.
• a "bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a "bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen).
• a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:
• lower alkyl refers to a C 1-4 straight or branched alkyl group.
• exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
• lower haloalkyl refers to a C 1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.
• heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
• the term "bivalent C 1 - S (or C 1-6 ) saturated or unsaturated, straight or branched, hydrocarbon chain” refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
• alkylene refers to a bivalent alkyl group.
• An "alkylene chain” is a polymethylene group, i.e., -(CH 2 )D-, wherein n is a positive integer, preferably from 1 to 6, from
• a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
• alkenylene refers to a bivalent alkenyl group.
• a substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
• cyclopropylenyl refers to a bivalent cyclopropyl group of
• halogen means F, Cl, Br, or I.
• aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or
• aryloxyalkyl refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
• aryl may be used interchangeably with the term “aryl ring.”
• aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or
• aryloxyalkyl refers to monocyclic and bicyclic ring systems having a total of five to 10 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members.
• aryl may be used interchangeably with the term “aryl ring”.
• aryl refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
• aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
• heteroaryl and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
• heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
• Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
• heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
• Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4i/-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin- 3(4H)-one.
• heteroaryl group may be mono- or bicyclic.
• heteroaryl may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted.
• heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
• heterocycle As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
• nitrogen includes a substituted nitrogen.
• the nitrogen may be N (as in 3,4- dihydro-2//-pyrrolyl), NH (as in pyrrolidinyl), or ⁇ R (as in iV-substituted pyrrolidinyl).
• N an organic radical
• NH an organic radical
• ⁇ R an organic radical
• a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
• saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
• heterocycle '"heterocyclyl
• heterocyclyl ring '"heterocyclic group
• heterocyclic moiety and “heterocyclic radical” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3i/-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring.
• a heterocyclyl group may be mono- or bicyclic.
• heterocyclylalkyl refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
• partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
• partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
• natural amino acid side-chain group refers to the side- chain group of any of the 20 amino acids naturally occuring in proteins.
• natural amino acids include the nonpolar, or hydrophobic amino acids, glycine, alanine, valine, leucine isoleucine, methionine, phenylalanine, tryptophan, and proline. Cysteine is sometimes classified as nonpolar or hydrophobic and other times as polar.
• Natural amino acids also include polar, or hydrophilic amino acids, such as tyrosine, serine, threonine, aspartic acid (also known as aspartate, when charged), glutamic acid (also known as glutamate, when charged), asparagine, and glutamine.
• Certain polar, or hydrophilic, amino acids have charged side-chains. Such charged amino acids include lysine, arginine, and histidine.
• One of ordinary skill in the art would recognize that protection of a polar or hydrophilic amino acid side -chain can render that amino acid nonpolar.
• a suitably protected tyrosine hydroxyl group can render that tyroine nonpolar and hydrophobic by virtue of protecting the hydroxyl group.
• the phrase "unnatural amino acid side-chain group” refers to the side- chain group of amino acids not included in the list of 20 amino acids naturally occuring in proteins, as described above. Such amino acids include the D-isomer of any of the 20 naturally occuring amino acids.
• Unnatural amino acids also include homoserine, ornithine, norleucine, and thyroxine.
• Other unnatural amino acids side-chains are well known to one of ordinary skill in the art and include unnatural aliphatic side chains.
• Other unnatural amino acids include modified amino acids, including those that are N-alkylated, cyclized, phosphorylated, acetylated, amidated, azidylated, labelled, and the like.
• an unnatural amino acid is a D-isomer.
• an unnatural amino acid is a L-isomer.
• substituted means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
• an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
• Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
• stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
• Suitable monovalent substituents on R° are independently halogen, -(CH 2 ) 0 2 R ⁇ , -(haloR'), -(CH 2 ) 0--2 OH, -(CH 2 ) 0-2 OR', -(CH 2 ) 0 2 CH(OR ⁇ ) 2 ; -O(haloR ⁇ ), -CN, -N 3 , -(CH 2 ) 0--2 C(O)R ⁇ , -(CH 2 ) 0--2 C(O)OH, -(CH 2 ) 0 2 C(O)OR ⁇ , -(CH 2 ) 0- 2 SR ⁇ , -(CH 2 ) 0-2 SH, -(CH 2 ) 0- 2 NH 2 , -(CH 2 ) 0-2 NHR ⁇ , -(CH 2 )
• Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -O(CR * 2 ) 2 3 O-, wherein each independent occurrence of R * is selected from hydrogen, C 1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• Suitable substituents on the aliphatic group of R include halogen, -R*, -(haloR'), -OH, -OR', -O(haloR'), -CN, -C(O)OH, -C(O)OR', -NH 2 , -NHR', -NR' 2 , or -NO 2 , wherein each R ⁇ is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C 1 ⁇ t aliphatic, -CH 2 Ph, -0(CH 2 ) 0- 1 Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R ⁇ , -NR ⁇ 2 , -C(O)R ⁇ , -C(O)OR ⁇ , -C(O)C(O)R ⁇ , -C(O)CH 2 C(O)R ⁇ , -S(O) 2 R ⁇ , -S(O) 2 NR ⁇ 2 , -C(S)NR ⁇ 2 , -C(NH)NR ⁇ 2 , or -N(R ⁇ S(O) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, C 1-6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrence
• Suitable substituents on the aliphatic group of R ⁇ are independently halogen, -R', -(haloR'), -OH, -OR', -O(haloR'), -CN, -C(O)OH, -C(O)OR', -NH 2 , -NHR', -NR' 2 , or -NO 2 , wherein each R ⁇ is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C 1-4 aliphatic, -CH 2 Ph, -0(CH 2 ) 0- iPh, or a 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
• Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
• Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
• Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
• inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
• organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
• salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
• Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and salts.
• Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
• Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
• structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
• structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
• Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
• a warhead moiety, R 3 of a provided compound comprises one or more deuterium atoms.
• an irreversible inhibitor will remain substantially bound to HCV protease once covalent bond formation has occurred.
• Irreversible inhibitors usually display time dependency, whereby the degree of inhibition increases with the time with which the inhibitor is in contact with the enzyme.
• an irreversible inhibitor will remain substantially bound to HCV protease once covalent bond formation has occurred and will remain bound for a time period that is longer than the life of the protein.
• Methods for identifying if a compound is acting as an irreversible inhibitor are known to one of ordinary skill in the art. Such methods include, but are not limited to, enzyme kinetic analysis of the inhibition profile of the compound with HCV protease, the use of mass spectrometry of the protein drug target modified in the presence of the inhibitor compound, discontinuous exposure, also known as "washout," experiments, and the use of labeling, such as radiolabeled inhibitor, to show covalent modification of the enzyme, as well as other methods known to one of skill in the art.
• warheads refers to a functional group present on a compound of the present invention wherein that functional group is capable of covalently binding to an amino acid residue (such as cysteine, lysine, histidine, or other residues capable of being covalently modified) present in the binding pocket of the target protein, thereby irreversibly inhibiting the protein.
• an amino acid residue such as cysteine, lysine, histidine, or other residues capable of being covalently modified
• an inhibitor is defined as a compound that binds to and /or inhibits HCV protease with measurable affinity.
• an inhibitor has an IC 50 and/or binding constant of less about 50 ⁇ M, less than about 1 ⁇ M, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
• a compound of the present invention may be tethered to a detectable moiety.
• a detectable moiety may be attached to a provided compound via a suitable substituent.
• suitable substituent refers to a moiety that is capable of covalent attachment to a detectable moiety.
• moieties are well known to one of ordinary skill in the art and include groups containing, e.g., a carboxylate moiety, an amino moiety, a thiol moiety, or a hydroxyl moiety, to name but a few.
• moieties may be directly attached to a provided compound or via a tethering group, such as a bivalent saturated or unsaturated hydrocarbon chain.
• such moieties may be attached via click chemistry.
• such moieties may be attached via a 1,3-cycloaddition of an azide with an alkyne, optionally in the presence of a copper catalyst.
• Methods of using click chemistry are known in the art and include those described by Rostovtsev et al, Angew. Chem. Int. Ed. 2002, 41, 2596-99 and Sun et al, Bioconjugate Chem., 2006, 17, 52-57.
• the term “detectable moiety” is used interchangeably with the term “label” and relates to any moiety capable of being detected, e.g., primary labels and secondary labels.
• Primary labels such as radioisotopes (e.g., tritium, 32 P, 33 P, 35 S, or 14 C), mass-tags, and fluorescent labels are signal generating reporter groups which can be detected without further modifications.
• Detectable moieties also include luminescent and phosphorescent groups.
• secondary label refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate for production of a detectable signal.
• the secondary intermediate may include streptavidin-enzyme conjugates.
• secondary intermediates may include antibody-enzyme conjugates.
• fluorescent label refers to moieties that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength.
• fluorescent labels include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665), Carboxyrhodamine 6G, carboxy
• mass-tag refers to any moiety that is capable of being uniquely detected by virtue of its mass using mass spectrometry (MS) detection techniques.
• mass-tags include electrophore release tags such as N-[3-[4'-[(p- Methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]isonipecotic Acid, 4 ' -[2,3 ,5 ,6- Tetrafluoro-4-(pentafluorophenoxyl)]methyl acetophenone, and their derivatives.
• mass-tags include, but are not limited to, nucleotides, dideoxynucleotides, oligonucleotides of varying length and base composition, oligopeptides, oligosaccharides, and other synthetic polymers of varying length and monomer composition.
• nucleotides dideoxynucleotides
• oligonucleotides of varying length and base composition oligopeptides, oligosaccharides
• other synthetic polymers of varying length and monomer composition.
• a large variety of organic molecules, both neutral and charged (biomolecules or synthetic compounds) of an appropriate mass range (100-2000 Daltons) may also be used as mass-tags.
• measurable affinity and “measurably inhibit,” as used herein, means a measurable change in HCV protease activity between a sample comprising a compound of the present invention, or composition thereof, and HCV protease, and an equivalent sample comprising HCV protease, in the absence of said compound, or composition thereof.
• the present invention provides a compound of formula I:
• R and R are independently hydrogen or optionally substituted C 1-6 aliphatic, or R and R are taken together to form an optionally substituted 3-7 membered carbocyclic ring;
• R 2a is -OH or -NHSO 2 R 2 ;
• R is -N(R) 2 or an optionally substituted group selected from C 3 _ 7 cycloalkyl, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen, optionally substituted C 1-6 aliphatic, or: two R on the same nitrogen atom are taken together with the nitrogen to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 3 is -L-Y, wherein:
• Y is hydrogen, C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 R e groups; and each R e is independently selected from -Q-Z, oxo, NO 2 , halogen, CN, a suitable leaving group, or a C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN, wherein: Q is a covalent bond or a bivalent C 1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by -N(R)-, -S-, -O-, -C(O)-, -OC(O)-, -
• R 4 is H, -NHC(O)R 5 , -NHC(O)OR 6 , ° R7 , or a natural or unnatural amino acid side -chain group; each R 5 is independently -N(R) 2 or an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• R 6 is an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and
• R 7 is an optionally substituted group selected from C 1-6 aliphatic, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and
• R z is ; or R 4 and R z are taken together with their intervening atoms to form an optionally substituted, saturated or unsaturated 16-22 membered ring having 2-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each occurrence of R y is independently selected from halogen, -OR°, -CN, -NO 2 , -N(R°) 2 , or optionally substituted C 1-4 aliphatic; and m is an integer from O to 4, inclusive; s is an integer from 0 to 4, inclusive; t is an integer from 0 to 4, inclusive; wherein the sum of s and t is non-zero.
• L is a covalent bond
• L is a bivalent C 1-8 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L are optionally and independently replaced by cyclopropylene, -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO 2 -,
• L is a bivalent C 1-8 saturated or unsaturated, straight or branched, hydrocarbon chain. In certain embodiments, L is -CH 2 -.
• L is a covalent bond, -CH 2 -, -NH-, -CH 2 NH-, -NHCH 2 -,
• L is a bivalent C 2 _ 8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two additional methylene units of L are optionally and independently replaced by -NRC(O)-, -C(O)NR-, -N(R)SO 2 -, -SO 2 N(R)-, -S-,
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by
• -C(O)- and one or two additional methylene units of L are optionally and independently replaced by cyclopropylene, -0-, -N(R)-, or -C(O)-.
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond.
• L has at least one double bond.
• a double bond may exist within the hydrocarbon chain backbone or may be "exo" to the backbone chain and thus forming an alkylidene group.
• L is a bivalent C2-8 straight or branched, hydrocarbon chain wherein L has at least one alkylidenyl double bond.
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by
• each R is independently hydrogen or optionally substituted C 1-6 aliphatic.
• L is a bivalent C 2 - 8 straight or branched, hydrocarbon chain wherein L has at least one triple bond.
• L is a bivalent C 2 - 8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and one or two additional methylene units of L are optionally and independently replaced by -NRC(O)-, -C(O)NR-, -S-,
• L has at least one triple bond and at least one methylene unit of L is replaced by -N(R)-, -N(R)C(O)-, -C(O)-,
• Exemplary L groups include -C ⁇ C-, -C ⁇ CCH 2 N(isopropyl)-, -NHC(O)C ⁇ CCH 2 CH 2 -,
• L is a bivalent C 2 _ 8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one or two additional methylene units of L are independently replaced by -C(O)-, -NRC(O)-, -C(O)NR-, -N(R)SO 2 -, or -SO 2 N(R)-.
• Exemplary L groups include -NHC(O)-cyclopropylene-SO 2 - and -NHC(O)- cyclopropylene-.
• Y is hydrogen, C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with at 1-4 R e groups, each R e is independently selected from -Q-Z, oxo, NO 2 , halogen, CN, a suitable leaving group, or C 1-6 aliphatic, wherein
• Q is a covalent bond or a bivalent C 1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by -N(R)-, -S-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO 2 -, -N(R)C(O)-, -
• Z is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN.
• Y is hydrogen
• Y is C 1-6 aliphatic optionally substituted with oxo, halogen,
• Y is C 2-6 alkenyl optionally substituted with oxo, halogen,
• Y is C 2-6 alkynyl optionally substituted with oxo, halogen,
• Y is C 2-6 alkenyl. In other embodiments, Y is C 2-4 alkynyl.
• Y is C 1-6 alkyl substituted with oxo, halogen, NO 2 , or CN.
• Y groups include -CH 2 F, -CH 2 Cl, -CH 2 CN, and -CH 2 NO 2 .
• Y is a saturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Y is substituted with 1 -4 R e groups, wherein each R e is as defined above and described herein.
• Y is a saturated 3-4 membered heterocyclic ring having 1 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-2 R e groups, wherein each R e is as defined above and described herein.
• Exemplary such rings are epoxide and oxetane rings, wherein each ring is substituted with 1-2 R e groups, wherein each R e is as defined above and described herein.
• Y is a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
• Such rings include piperidine and pyrrolidine, wherein each ring is substituted with 1-4 R e groups, wherein each R e is as defined
• Y is or , wherein each R, Q, Z, and R e is as defined above and described herein.
• Y is a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
• Y is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein each ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein..
• Y is , wherein R e is as defined above and described herein. In certain embodiments, Y is cyclopropyl optionally substituted with halogen, CN or NO 2 . [0086] In certain embodiments, Y is a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein. [0087] In some embodiments, Y is a partially unsaturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
• Y is cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl wherein each ring is substituted with 1-4 R e groups, wherein each R e is as defined
• Y is , wherein each R is as defined above and described herein.
• Y is a partially unsaturated 4-6 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
• Y is selected from:
• each R and R e is as defined above and described herein.
• Y is a 6-membered aromatic ring having 0-2 nitrogens wherein said ring is substituted with 1-4 R e groups, wherein each R e group is as defined above and described herein.
• Y is phenyl, pyridyl, or pyrimidinyl, wherein each ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein.
• Y is selected from:
• each R e is as defined above and described herein.
• Y is a 5 -membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 R e groups, wherein each R e group is as defined above and described herein.
• Y is a 5 membered partially unsaturated or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein said ring is substituted with 1- 4 R e groups, wherein each R e group is as defined above and described herein.
• rings are isoxazolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyrrolyl, furanyl, thienyl, triazole, thiadiazole, and oxadiazole, wherein each ring is substituted with 1-3 R e groups, wherein each R e group is as defined above and described herein.
• Y is selected from:
• each R and R e is as defined above and described herein.
• Y is an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein.
• Y is a 9-10 membered bicyclic, partially unsaturated, or aryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein.
• Exemplary such bicyclic rings include 2,3-dihydrobenzo[d]isothiazole, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein.
• each R e group is independently selected from -Q-Z, oxo,
• halogen CN
• a suitable leaving group or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN
• Q is a covalent bond or a bivalent C 1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by -N(R)-, -S-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -SO-, or -SO 2 -, -
• Z is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN.
• R e is C 1-6 aliphatic optionally substituted with oxo, halogen,
• R e is oxo, NO 2 , halogen, or CN.
• R e is -Q-Z, wherein Q is a covalent bond and Z is hydrogen (i.e., R e is hydrogen).
• R e is -Q-Z, wherein Q is a bivalent C 1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by -NR-, -NRC(O)-, -C(O)NR-, -S-, -O-, -C(O)-, -SO-, or -SO2-.
• Q is a bivalent C 2-6 straight or branched, hydrocarbon chain having at least one double bond, wherein one or two methylene units of Q are optionally and independently replaced by -NR-, -NRC(O)-, -C(O)NR-, -S-, -O-, -C(O)-, -SO-, or -SO 2 -.
• the Z moiety of the R e group is hydrogen.
• R e is a suitable leaving group, ie a group that is subject to nucleophilic displacement.
• a “suitable leaving” is a chemical group that is readily displaced by a desired incoming chemical moiety such as the thiol moiety of a cysteine of interest.
• Suitable leaving groups are well known in the art, e.g., see, “Advanced Organic Chemistry,” Jerry March, 5 th Ed., pp. 351-357, John Wiley and Sons, N.Y.
• Such leaving groups include, but are not limited to, halogen, alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, acyl, and diazonium moieties.
• Suitable leaving groups include chloro, iodo, bromo, fluoro, acetoxy, methanesulfonyloxy (mesyloxy), tosyloxy, triflyloxy, nitro-phenylsulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy).
• L is a bivalent C 2 _ 8 straight or branched, hydrocarbon chain wherein L has at least one double bond and one or two additional methylene units of L are optionally and independently replaced by -NRC(O)-, -C(O)NR-, -N(R)SO 2 -, -SO 2 N(R)-, -S-, -S(O)-, -SO 2 -, -OC(O)-, -C(O)O-, cyclopropylene, -0-, -N(R)-, or -C(O)- ; and Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• L is a bivalent C 2 _ 8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -C(O)-, -NRC(O)-, -C(O)NR-, -N(R)SO 2 -, -SO 2 N(R)-, -S-, -S(O)-, -SO 2 -, -OC(O)-, or -C(O)O-, and one or two additional methylene units of L are optionally and independently replaced by cyclopropylene, -0-, -N(R)-, or -C(O)-; and Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -C(O)-, and one or two additional methylene units of L are optionally and independently replaced by cyclopropylene, -0-, -N(R)-, or -C(O)-; and Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -C(O)-; and Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• L is a bivalent C 2 _ 8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by -OC(O)-; and Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one alkylidenyl double bond and at least one methylene unit of L is replaced by -C(O)-, -NRC(O)-, -C(O)NR-, -N(R)SO 2 -, -SO 2 N(R)-, -S-, -S(O)-, -SO 2 -, -OC(O)-, or -C(O)O-, and one or two additional methylene units of L are optionally and independently replaced by cyclopropylene, -O-, -N(R)-, or -C(O)-; and Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• L is a bivalent C 2 - 8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and one or two additional methylene units of L are optionally and independently replaced by -NRC(O)-, -C(O)NR-, -N(R)SO 2 -, -SO 2 N(R)-, -S-, -S(O)-, -SO2-, -OC(O)-, or -C(O)O-, and Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• (k) L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one or two additional methylene units of L are independently replaced by -NRC(O)-, -C(O)NR-, -N(R)SO 2 -, -SO 2 N(R)-, -S-, -S(O)-, -SO 2 -, -OC(O)-, or -C(O)O-; and Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN; or
• L is a covalent bond and Y is selected from:
• each R, Q, Z, and R e is as defined above and described herein; or iyi ⁇ ) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein; or
• each R e is as defined above and described herein;
• each R e is as defined above and described herein;
• R e is as defined above and described herein; or (v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 R e groups, wherein each
• R e is as defined above and described herein; or
• each R, Q, Z, and R e is as defined above and described herein; or (vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4
• R e groups wherein each R e is as defined above and described herein; or (vii ⁇ ) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein, or
• each R e is as defined above and described herein;
• each R and R e is as defined above and described herein;
• each R e is as defined above and described herein;
• each R and R e is as defined above and described herein; or (xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein; (n) L is -N(R)C(O)- and Y is selected from:
• R e is as defined above and described herein; or (v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 R e groups, wherein each
• R e is as defined above and described herein; or
• each R, Q, Z, and R e is as defined above and described herein; or (vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4
• R e groups wherein each R e is as defined above and described herein; or (viii) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein, or
• each R e is as defined above and described herein;
• each R e is as defined above and described herein;
• each R and R e is as defined above and described herein; or (xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein; L is a bivalent C 1 -S saturated or unsaturated, straight or branched, hydrocarbon chain; and Y is selected from:
• R e is as defined above and described herein; or (v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 R e groups, wherein each
• R e is as defined above and described herein; or
• each R, Q, Z, and R e is as defined above and described herein; or (vti) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4
• R e groups wherein each R e is as defined above and described herein; or (viif) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein, or
• each R e is as defined above and described herein;
• each R e is as defined above and described herein;
• each R and R e is as defined above and described herein; or (xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein;
• (n) L is a covalent bond, -CH 2 -, -NH-, -C(O)-, -CH 2 NH-, -NHCH 2 -, -NHC(O)-, -NHC(O)CH 2 OC(O)-, -CH 2 NHC(O)-, -NHSO 2 -, -NHSO 2 CH 2 -, -NHC(O)CH 2 OC(O)-, or -SO 2 NH-; and Y is selected from: (/) C 1-6 alkyl substituted with oxo, halogen, NO 2 , or CN; or (H) C 2 - 6 alkenyl optionally substituted with oxo, halogen, NO 2 , or CN; or (Hi) C 2 _6 alkynyl optionally substituted with oxo, halogen, NO 2 , or CN; or (iv) a saturated 3-4 membered heterocyclic ring having 1 hetero
• R e is as defined above and described herein; or (v) a saturated 5-6 membered heterocyclic ring having 1-2 heteroatom selected from oxygen or nitrogen wherein said ring is substituted with 1-4 R e groups, wherein each
• R e is as defined above and described herein; or
• each R, Q, Z, and R e is as defined above and described herein; or (vii) a saturated 3-6 membered carbocyclic ring, wherein said ring is substituted with 1-4
• R e groups wherein each R e is as defined above and described herein; or (vii ⁇ ) a partially unsaturated 3-6 membered monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein each R e is as defined above and described herein, or
• each R and R e is as defined above and described herein;
• each R e is as defined above and described herein;
• JV a 5 -membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-3 R e groups, wherein each R e group is as defined above and described herein; or
• each R and R e is as defined above and described herein; or (xvii) an 8-10 membered bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with 1-4 R e groups, wherein R e is as defined above and described herein.
• the Y group of formula I is selected from those set forth in Table 1 , below, wherein each wavy line indicates the point of attachment to the rest of the molecule.
• each R e is independently a suitable leaving group, NO 2 , CN, or oxo.
• the R 3 group of formula I is selected from those set forth in Table 2, below, wherein each wavy line indicates the point of attachment to the rest of the molecule.
• VVVVV wwwww xxxxx yyyyy zzzzz aaaaaa bbbbbbb
• each R e is independently a suitable leaving group, NO2, CN, or oxo.
• the R and R groups of formula I are independently hydrogen or optionally substituted C 1-6 aliphatic.
• R 1 is hydrogen and R 1 is C 1-4 aliphatic.
• R 1 is hydrogen and R 1 is n-propyl.
• the R and R groups of formula I are taken together to form an optionally substituted 3-7 membered carbocyclic ring. In some embodiments, the R 1 and R 1 groups of formula I are taken together to form an optionally substituted cyclopropyl ring. In some embodiments, the R 1 and R 1 groups of formula I are taken together to form a cyclopropyl ring substituted with ethyl or vinyl.
• R 4 is H, -NHC(O)R 5 , -NHC(O)OR 6 , or or R 4 and R z are taken together with their intervening atoms to form an optionally substituted, saturated or unsaturated 16-22 membered ring having 2-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• the R 4 group of formula I is -NHC(O)R 5 . In some embodiments, the R 4 group of formula I is -NHC(O)OR 6 . In other embodiments, the R 4 group of
• formula I is .
• the R 4 group of formula I is hydrogen.
• R 4 is -NHC(O)R 5
• R 5 is C 1-6 aliphatic or an optionally substituted group selected from a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or A-
• R 6 is C 1-6 aliphatic or an optionally substituted group selected from a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or A-
• the R 4 group of formula I is an amino acid side-chain group.
• the R group of formula I is an unnatural amino acid side-chain group.
• the R 4 group of formula I is an aliphatic unnatural amino acid side-chain group. In some embodiments, the R 4 group of formula I is an unnatural amino acid side-chain group of alanine substituted with one, two, or three R° groups, wherein each R° is as defined above. In some embodiments, the R group of formula I is a natural amino acid side-chain group.
• the R group of formula I is the natural amino acid side- chain group of alanine (i.e., R 4 is methyl). In some embodiments, the R 4 group of formula I is the natural amino acid side-chain group of D-alanine. In some embodiments, the R 4 group of formula I is the natural amino acid side-chain group of L-alanine.
• the R 4 group of formula I is the natural amino acid side-chain group of valine. In some embodiments, the R group of formula I is the natural amino acid side- chain group of D-valine. In some embodiments, the R 4 group of formula I is the natural amino acid side-chain group of L-valine.
• the R group of formula I consists of a mixture of amino acid side-chain groups in both the D- and L- configuration. Such R 4 groups are referred to herein as "D,L-mixed amino acid side-chain groups.” In some embodiments, the ratio of D- to L-amino acid side-chain groups is selected from any of 6:1, 5:1, 4:1, 3:1, 2:1, 1 :1, 1 :2, 1:3, 1 :4; 1:5, and 1:6. Thus, in certain embodiments, the R 4 group of formula I is a D,L-mixed alanine side-chain group. In other embodiments, the R 4 group of formula I is a D,L-mixed valine side-chain group.
• the R- and R groups of formula I are independently optionally substituted groups selected from optionally substituted group selected from C 1-6 aliphatic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• R 5 is an optionally substituted 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur
• R 7 is an optionally substituted C 1-6 aliphatic group.
• R 5 is and R 7 is cyclohexyl.
• R is -NHC(O)R , wherein R is independently -N(R) 2 or an optionally substituted group selected from C 1-6 aliphatic.
• R 5 is -N(R) 2 and each R is independently hydrogen, optionally substituted C 1-6 aliphatic, or two R on the same nitrogen atom are taken together with the nitrogen to form a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• R is -N(R) 2 and each R is independently hydrogen or t-butyl.
• the R 5 group of formula I is an optionally substituted 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• R is an optionally substituted 6 membered heteroaryl ring having 1-2 nitrogens.
• R 5 is piperazinyl.
• the R group of formula I is an optionally substituted C 1-6 aliphatic group.
• R 7 is a branched C 1 -S alkyl group. In other embodiments, R 7 is cyclopentyl or cyclohexyl.
• R z is In certain embodiments, R z is
• R z is In certain embodiments,
• R z is In certain embodiments, R z is
• R z is . In certain embodiments, R z is
• R y is halogen. In other embodiments, R y is C M aliphatic. In certain embodiments, R y is fluoro. In certain embodiments, R y is chloro. In certain embodiments, R y is bromo. In certain embodiments, R y is iodo. In other embodiments, R y is vinyl.
• m is an integer between 1 and 3, inclusive. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.
• s is an integer between 1 and 3, inclusive. In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3. In some embodiments, s is 4.
• t is an integer between 1 and 3, inclusive. In some embodiments, t is 0. In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, t is 3. In some embodiments, t is 4.
• the R 2a group of formula I is -OH. In other embodiments, the R 2a group of formula I is -NHSO 2 R 2 , wherein R 2 is as defined above and described herein.
• the present invention provides a compound of formula I-a or I-b:
• the R group of formula I-b is -N(R) 2 .
• the R 2 group of formula I-b is an optionally substituted group selected from C 3 . 7 cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-
• heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• R is C 3 _ 7 cycloalkyl or 6-10 membered aryl. In some embodiments, R is optionally substituted
• R 2 is phenyl. In certain embodiments, R 2 is cyclopropyl.
• R is selected from C 3 _ 7 cycloalkyl, a bridged bicyclic, 6-10 membered aryl, 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 4-7 membered heterocyclyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• the R group of formula I is a warhead group.
• the R 3 and R 1 groups of formula I are taken together with their intervening atoms to form an optionally substituted saturated or unsaturated 12-18 membered ring having 2-6 heteroatoms independently selected from nitrogen oxygen, or sulfur, wherein the ring formed thereby comprises a warhead group.
• R 3 and a ring formed by R 1 and R 1 are taken together with their intervening atoms to form an optionally substituted saturated or unsaturated 12-18 membered ring having 2-6 heteroatoms independently selected from nitrogen oxygen, or sulfur, wherein the ring formed thereby comprises a warhead group.
• the ring formed by the R 3 and R 1 groups of formula I comprises a warhead group.
• the phrase "comprises a warhead group” means that the ring formed by R and R is either substituted with a warhead group or has such a warhead group incorporated within the ring.
• the ring formed by R 3 and R 1 may be substituted with an -L-Y warhead group, wherein such groups are as described herein.
• the ring formed by R J and R 1 has the appropriate features of a warhead group incorporated within the ring.
• the ring formed by R 3 and R 1 may include one or more units of unsaturation and optional substituents and/or heteroatoms which, in combination, result in a moiety that is capable of covalently modifying HCV protease in accordance with the present invention.
• the ring formed by R and R is optionally substituted at the ⁇ -, ⁇ -, or ⁇ -position with respect to the carbon to which R 4 is attached.
• R 3 and R 1 are taken together with their intervening atoms to form an optionally substituted saturated or unsaturated 12-18 membered ring having 2-6 heteroatoms independently selected from nitrogen oxygen, or sulfur, such compounds include those wherein R 3 and a ring formed by R 1 and and R 1 are taken together.
• Exemplary compounds of formula I wherein R 3 and a ring formed by R 1 and R 1 are taken together include those of formula I-c-1, 1-c-2, 1-c-3, 1-c-4, 1-c-5-, and I-c-6:
• Exemplary such compounds include those set forth in Table 3, infra.
• compounds of formulae I-c-1, I-c-2, I-c-3, I-c-4, I-c-5, and I-c-6 are depicted as having (Z)-double bond stereochemistry in the macrocyclic ring, it will be understood that, in certain embodiments, compounds of formulae I-c-1, I-c-2, I-c-3, I-c-4, I-c-5, and I-c-6 may be provided having (E)-double bond stereochemistry in the macrocylic ring. In some embodiments, mixtures of both stereoisomers are provided. In other embodiments, compounds of formulae I-c- 1, I-c-2, I-c-3, I-c-4, I-c-5, and I-c-6 may be treated under suitable conditions to saturate the double bond.
• R 1 and R 1 are taken together to form an optionally substituted 3-7 membered carbocyclic ring.
• such compounds are of formula I-d:
• R , R , R z , and R° is as defined in formula I and described in classes and subclasses above and herein.
• R° is an optionally substituted group selected from C 1-6 aliphatic. In some embodiments, R° is ethyl. In other embodiments, R° is vinyl. [00132] Exemplary R 3 groups of formula I-d include those described above and herein, as well as those depicted in Table 3, below.
• R 4 and R z are taken together with their intervening atoms to form an optionally substituted, saturated or unsaturated 16-22 membered ring having 2-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R 4 and R z are taken together with their intervening atoms to form an optionally substituted, unsaturated 18-22 membered ring having 3-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• the ring formed by R 4 and R z is substituted with one or more R m groups, wherein each occurrence of R m is independently halogen, -OR°; -CN; -SCN; - SR°; -SOR°; -SO 2 R°; -NO 2 ; -N(R°) 2 ; -NHC(O)R°, or an optionally substituted group selected from the group consisting of C 1-6 aliphatic and C 3-7 cycloalkyl.
• the present invention provides compounds of formula I-e or I-f :
• each of m, s, t, R 2a , R 3 , R y , and R° is as defined in formula I and described in classes and subclasses above and herein; p is an integer from 1 to 6, inclusive; and each occurrence of R m is independently halogen, -OR°; -CN; -N(R°) 2 ; or an optionally substituted group selected from the group consisting of C 1-6 aliphatic and C3-7 cycloalkyl.
• p is 1. In some embodiments, p is 2.
• R m is C 1-6 aliphatic. In some embodiments, R m is methyl.
• R° is an optionally substituted group selected from C 1-6 aliphatic. In some embodiments, R° is ethyl. In other embodiments, R° is vinyl.
• R 3 groups of formulae I-e and I-f include those described herein and depicted in Table 3, below.
• compounds of formulae I-e and I-f are depicted as having either (Z) or (E) double bond stereochemistry in the macrocyclic ring, it will be understood that, in certain embodiments, compounds of formulae I-e and I-f may be provided having (E)-double bond stereochemistry in the macrocyclic ring. In certain embodiments, compounds of formulae I-e and I-f may be provided having (Z)-double bond stereochemistry in the macrocylic ring. In some embodiments, mixtures of both stereoisomers are provided.
• compounds of formulae I-e and I-f may be treated under suitable conditions to saturate the double bond, thereby forming a compound of formula I-g or I-h: i-g I-h or a pharmaceutically acceptable salt thereof.
• R 4 and R z are taken together as described above, and R 3 and a ring formed by R 1 and R 1 ' are taken together as described above, to form novel bimacrocyclic compounds.
• the ring formed by R and R z is substituted with one or more R m groups as described above for formulae I-e and I-f.
• the macrocyclic ring formed by R 3 and a ring formed by R 1 and R 1 ' is substituted with an -L-Y warhead group to provide a compound of formula I-j or I-k:
• ⁇ independently represents a single or double bond.
• Methods of preparing such compounds, in addition to those described herein for the synthesis of other macrocycles and compounds incorporating a warhead, include those described by McCauley, J.A. et al, Angew. Chem. Int. Ed., 2008, 47, pp. 9104-7.
• a methylene unit of the macrocyclic ring formed by R and a ring formed by R 1 and R 1 ' is replaced by an L-Y moiety to provide a compound of formula I-m or I-n:
• the R 4 group for compounds of formula I is hydrogen.
• the present invention provides a compound of formula II-a or II-b:
• each of the R , R , R , and R z groups is as defined for formula I above and described in classes and subclasses herein.
• the present invention provides any compound depicted in Table 3, above, or a pharmaceutically acceptable salt thereof.
• R 3 is a warhead group.
• R groups i.e. warhead groups
• such R groups are particularly suitable for covalently binding to a key cysteine residue in the binding domain of HCV protease.
• HCV protease, and mutants thereof have a cysteine residue in the binding domain.
• compounds of the present invention have a warhead group characterized in that inventive compounds may target the C 159 cysteine residue of HCV protease.
• R ⁇ is characterized in that the -L-Y moiety is capable of covalently binding to a cysteine residue thereby irreversibly inhibiting the enzyme.
• the cysteine residue is Cysl59 of HCV protease, or a mutant thereof, where the provided residue numbering is in accordance with Uniprot (code Q91RS4).
• R groups include, but are not limited to, those described herein and depicted in Table 3, supra. This phenomenon may be determined by performing mass spectroscopic experiments using the protocol described in detail in Examples 17 through 21, infra.
• the present invention provides a conjugate comprising HCV protease, or a mutant thereof, covalently bonded to an inhibitor at Cysl59.
• the inhibitor is covalently bonded via a linker moiety.
• the present invention provides a conjugate of the formula Cysl59-linker-inhibitor moiety.
• the "linker” group corresponds to an -L-Y warhead group as described herein. Accordingly, in certain embodiments, the linker group is as defined for -L-Y was defined above and described in classes and subclasses herein. It will be appreciated, however, that the linker group is bivalent and, therefore, the corresponding -L-Y group is also intended to be bivalent resulting from the reaction of the warhead with the Cysl59 of HCV protease, or a mutant thereof.
• the inhibitor moiety is a compound of formula A:
• each of the R 1 , R 1 , R 2a , R 4 , and R z groups of formula A is as defined for formula I above and described in classes and subclasses herein.
• the present invention provides a conjugate of the formula: wherein each of the R 1 , R 1 , R 2a , R 4 , and R z groups of the conjugate is as defined for formula I above and described in classes and subclasses herein.
• R 3 is characterized in that the -L-Y moiety is capable of covalently binding to a cysteine residue thereby irreversibly inhibiting the enzyme.
• the cysteine residue is Cys16 of HCV protease, or a mutant thereof, where the provided residue numbering is in accordance with Uniprot (code Q91RS4).
• the present invention provides a conjugate comprising
• HCV protease or a mutant thereof, covalently bonded to an inhibitor at Cys16.
• the inhibitor is covalently bonded via a linker moiety.
• the present invention provides a conjugate of the formula
• linker group corresponds to an -L-Y warhead group as described herein. Accordingly, in certain embodiments, the linker group is as defined for -L-Y was defined above and described in classes and subclasses herein. It will be appreciated, however, that the linker group is bivalent and, therefore, the corresponding -L-Y group is also intended to be bivalent resulting from the reaction of the warhead with the Cys16 of HCV protease, or a mutant thereof.
• the inhibitor moiety is a compound of formula A-I :
• each of the R 1 , R 1 , R 2a , R 4 , and R z groups of formula A-I is as defined for formula I above and described in classes and subclasses herein.
• the present invention provides a conjugate of the formula: wherein each of the R 1 , R 1 , R 2a , R 4 , and R z groups of the conjugate is as defined for formula I above and described in classes and subclasses herein.
• the present compounds are generally prepared according to
• the present invention provides methods for preparing compounds of formula I, according to the steps depicted in Scheme 1 above wherein each variable is as defined and described herein and each PG is a suitable protecting group.
• an N-protected (e.g. Boc) proline derivative of formula A is condensed with an alpha-aminoester of formula B using peptide coupling conditions to give a dipeptide of formula C.
• Suitable peptide coupling conditions are well known in the art and include those described in detail in PCT publication number WO2002094822 (US6825347), the entirety of which is hereby incorporated by reference. Unless otherwise indicated, said conditions are referenced as suitable peptide coupling conditions throughout this application.
• the ester group is hydrolyzed with a suitable base and subsequently neutralized to give a dipeptide of formula D.
• suitable bases include, but are not limited to, alkaline metals, alkaline earth metal hydroxides, and combinations thereof.
• the base is lithium hydroxide.
• a dipeptide of formula D is coupled with a sulfonamide of formula E using suitable peptide coupling conditions to give an acylsulfonamide of formula F.
• cleavage of the protective group e.g. Boc removal
• cleavage of the Boc group is achieved by contacting a compound of formula F with a mineral or organic acid in a halogenated hydrocarbon solvent.
• the acid is trifluoroacetic acid and the solvent is dichloromethane.
• step S-5 an amine of formula G is coupled with an carboxylic acid of formula H using suitable peptide coupling conditions to give an intermediate compound of formula 1-0.
• Intermediate compound of formula 1-0 is converted to compounds of formula I in steps which are described as examples herein.
• the PG group of formulae A, C, D, and F is a suitable amino protecting group.
• Suitable amino protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference.
• Protected amines are well known in the art and include those described in detail in Greene (1999).
• Suitable mono-protected amines further include, but are not limited to, aralkylamines, carbamates, allyl amines, amides, and the like.
• Suitable mono- protected amino moieties include t-butyloxycarbonylamino (-NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (-NHAlloc), benzyloxocarbonylamino (-NHCBZ), allylamino, benzylamino (-NHBn), fluorenylmethylcarbonyl (-NHFmoc), formamido, acetamido, chloroacetamido, dichloroacetamido, trichloroacetamido, phenylacetamido, trifluoroacetamido, benzamido, t- butyldiphenylsilyl, and the like.
• Suitable di-protected amines include amines that are substituted with two substituents independently selected from those described above as mono-protected amines, and further include cyclic imides, such as phthalimide, maleimide, succinimide, and the like.
• the present invention provides methods for preparing compounds of formula I, according to the steps depicted in Scheme 1 above.
• step S-6 removal of the Boc group from a dipeptide of formula C is achieved under acid-catalyzed conditions to give a dipeptide ester of formula J.
• a dipeptide ester of formula J is condensed with a functionalized amino acid of formula H using suitable peptide coupling conditions to give a tripeptide ester of formula
• the ester group on a compound of formula L is hydrolyzed with a suitable base and subsequently neutralized to give a tripeptide of formula M.
• suitable bases include, but are not limited to, alkaline metals, alkaline earth metal hydroxides, and combinations thereof.
• the base is lithium hydroxide.
• step S-9 a tripeptide of formula M is condensed with a sulfonamide of formula E using suitable peptide coupling conditions to give compounds of formula I.
• the PG group of formulae C, H, and K is a suitable amino protecting group as described above.
• compositions are provided.
• the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
• the amount of compound in compositions of this invention is such that is effective to measurably inhibit HCV protease, or a mutant thereof, in a biological sample or in a patient.
• the amount of compound in compositions of this invention is such that is effective to measurably inhibit HCV protease, or a mutant thereof, in a biological sample or in a patient.
• a composition of this invention is formulated for administration to a patient in need of such composition.
• a composition of this invention is formulated for oral administration to a patient.
• the term "patient,” as used herein, means an animal, preferably a mammal, and most preferably a human.
• pharmaceutically acceptable carrier, adjuvant, or vehicle refers to a nontoxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
• compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
• ion exchangers alumina, aluminum stearate, lecithin
• serum proteins such as human serum albumin
• buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate,
• a "pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
• compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
• parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
• the compositions are administered orally, intraperitoneally or intravenously.
• Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
• the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
• sterile, fixed oils are conventionally employed as a solvent or suspending medium.
• any bland fixed oil may be employed including synthetic mono- or di-glycerides.
• Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
• These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
• Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
• compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
• carriers commonly used include lactose and corn starch.
• Lubricating agents such as magnesium stearate, are also typically added.
• useful diluents include lactose and dried cornstarch.
• aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
• compositions of this invention may be administered in the form of suppositories for rectal administration.
• suppositories for rectal administration.
• suppositories can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
• suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
• compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
• Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
• provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
• Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
• provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
• Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
• compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
• the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
• compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents. [00182] Most preferably, pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.
• compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
• a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
• the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
• Compounds and compositions described herein are generally useful for the inhibition of HCV protease activity and/or the activity of a mutant thereof.
• provided compounds are useful for treating non-A, non-B hepatitis, including hepatitis C.
• HCV is an extremely variable virus that forms polymorphic swarms of variants within the host.
• genotypes have now been defined (Simmonds et ai, Hepatology, Vol. 42, No. 4, 2005). These genotypes have been further classified into more closely related, genetically distinct subtypes. Comparative sequence portions, known as consensus sequences, are set forth in Table 3a, below.
• HCV genotypes and subtypes are distributed differently in different parts of the world, and certain genotypes predominate in certain areas. Genotypes 1-3 are widely distributed throughout the world. Subtype Ia is prevalent in North and South America, Europe, and Australia. Subtype Ib is common in North America and Europe, and is also found in parts of Asia. Genotype 2 is present in most developed countries, but is less common than genotype 1
• genotypes are prevalent in ex-US patient populations and are therefore important targets.
• a cysteine located at amino acid position 159 in genotype Ib is conserved in all genotypes and subtypes of HCV NS3 sequenced to date, although the amino acid position may be different in other genotypes and subtypes. Targeting this cysteine residue with irreversible inhibitors should enable the development of agents which are effective against multiple HCV genotypes.
• the present invention provides irreversible inhibitors of one or more HCV protease genotypes, and variants thereof.
• Such compounds comprising a warhead group designated as R 3 , include those of formulae I, I-a, I-b, I-c-1, 1-c-2, 1-c-3, 1-c-4, 1-c-5, 1-c- 6, I-d, I-e, I-f, I-g, I-h, II-a, and II-b, as described herein.
• R 3 is characterized in that the -L-Y moiety is capable of covalently binding to a cysteine residue thereby irreversibly inhibiting the enzyme.
• R 3 groups i.e. warhead groups
• one or more genotypes inhibited by compounds of the present invention include Ia, Ib, 2a, and 3a.
• one or more such variants include A156T, A156S, D168V, D168A, and R155K.
• HCV protease genotypes and variants thereof have one or more cysteine residues near the binding domain.
• the cysteine residue of interest is Cysl59 of HCV protease subtype Ib, or a variant thereof, where the provided residue numbering is in accordance with Uniprot (code Q91RS4).
• Cysteine residues of other HCV protease genotypes and subtypes suitable for covalent modification by irreversible inhibitors of the present invention include those summarized in Table 3a, below, where the bold and underlined "C” refers to a cysteine residue conserved at an equivalent position to Cysl59 of HCV protease subtype Ib.
• genotype consensus sequences described herein are representative of a given genotype or subtype. Such representative consensus sequences are available at http://hcv.lanl. gov/content/sequence/NEWALIGN/align.html.
• BILN 2061 and VX-950 are depicted below.
• HCV protease mutants include A156T, A156S, D168V, and D168A and R155K.
• HCV protease inhibitors e.g., VX-950 and BILN 2061
• no drug described in the prior art has been shown to be an effective inhibitor of all known HCV protease mutants.
• Tables 4a and 4b below where the BILN 2061 and VX-950 data are as reported by Lin et al. and elsewhere in the HCV literature, and the data for compound 1-3 was obtained according to methods set forth in the Examples, infra.
• compounds of the present invention may be effective inhibitors of drug resistant forms of HCV protease. While Table 4b shows compound 1-3 activity against four reference HCV variants (A156T, A156S, D168V, and D168A), the ensuing examples will describe other provided compounds of the invention that are active against these variants as well as a fifth (Rl 55K) variant.
• a compound of formula I is more effective at inhibiting HCV protease, or a mutant thereof, as compared to a corresponding compound of formula I wherein the R moiety of formula I is instead a non- warhead group, such as straight alkyl (e.g., unsubstituted alkyl), branched alkyl, cycloalkyl, or alkenyl.
• R moiety of formula I is instead a non- warhead group, such as straight alkyl (e.g., unsubstituted alkyl), branched alkyl, cycloalkyl, or alkenyl.
• a compound of formula I can be more effective at inhibition of HCV protease, or a mutant thereof, as compared to a corresponding compound of formula I wherein the R 3 moiety of formula I is instead a non-warhead moiety such as methyl, ethyl, propyl, butyl (e.g., t-butyl), unsubstituted straight or branched alkenyl (e.g. C 1 - S alkenyl), cyclohexyl, or cyclopentyl.
• the R 3 moiety of formula I is instead a non-warhead moiety such as methyl, ethyl, propyl, butyl (e.g., t-butyl), unsubstituted straight or branched alkenyl (e.g. C 1 - S alkenyl), cyclohexyl, or cyclopentyl.
• a compound of formula I can be more potent with respect to an IC50 against HCV protease, or a mutant such as A156T, A156S, D168V, D168A, or other mutants such as those disclosed herein, than a corresponding compound of formula I wherein the R moiety of formula I is instead a non- warhead moiety such as methyl, ethyl, propyl, butyl (e.g., t-butyl), unsubstituted straight or branched alkenyl (e.g. C 1-8 alkenyl), cyclohexyl, or cyclopentyl.
• a non- warhead moiety such as methyl, ethyl, propyl, butyl (e.g., t-butyl), unsubstituted straight or branched alkenyl (e.g. C 1-8 alkenyl), cyclohexyl, or cyclopentyl.
• Such comparative potency of a compound of formula I as compared to a corresponding compound of formula I wherein the R 3 moiety of formula I is instead a non- warhead moiety can be determined by standard time-dependent assay methods, such as those described in detail in the Examples section, infra.
• a compound of formula I is measurably more potent than a corresponding compound of formula I wherein the R moiety of formula I is instead a non- warhead moiety such as methyl, ethyl, propyl, butyl (e.g., t-butyl), unsubstituted straight or branched alkenyl (e.g.
• a compound of formula I is measurably more potent, wherein such potency is observed after about 1 minute, about 2 minutes, about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 8 hours, about 12 hours, about 16 hours, about 24 hours, or about 48 hours, than a corresponding compound of formula I wherein the R 3 moiety of formula I is instead a non-warhead moiety such as methyl, ethyl, propyl, butyl (e.g., t-butyl), unsubstituted straight or branched alkenyl (e.g.
• a compound of formula I is any of about 1.5 times, about 2 times, about 5 times, about 10 times, about 20 times, about 25 times, about 50 times, about 100 times, or even about 1000 times more potent than a corresponding compound of formula I wherein the R 3 moiety of formula I is instead a non- warhead moiety such as methyl, ethyl, propyl, butyl (e.g., t-butyl), unsubstituted straight or branched alkenyl (e.g. C 1-8 alkenyl), cyclohexyl, or cyclopentyl.
• the term “clinical drug resistance” refers to the loss of susceptibility of a drug target to drug treatment as a consequence of mutations in the drug target
• the term “resistance” refers to changes in the wild-type nucleic acid sequence coding a target protein, and/or the protein sequence of the target, which changes decrease or abolish the inhibitory effect of the inhibitor on the target protein.
• Examples of proteases that are inhibited by the compounds and compositions described herein and against which the methods described herein are useful include NS3, NS3*4A, or a mutant thereof.
• the activity of a compound utilized in this invention as an inhibitor of NS3, NS3 » 4A, or a mutant thereof may be assayed in vitro, in vivo or in a cell line.
• In vitro assays include assays that determine inhibition of either the serine protease activity and/or the subsequent functional consequences, or ATPase activity of activated NS3, NS3 » 4A, or a mutant thereof.
• Alternate in vitro assays quantitate the ability of the inhibitor to bind to NS3 or NS3 » 4A.
• Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/NS3 or inhibitor/ NS3 » 4A complex and determining the amount of radiolabel bound.
• inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with NS3 or NS3*4A bound to known radioligands.
• Detailed conditions for assaying a compound utilized in this invention as an inhibitor of NS3 or NS3 » 4A, or a mutant thereof, are set forth in the Examples below.
• Serine proteases are a large family of proteolytic enzymes that cleave peptide bonds in proteins.
• the serine protease family includes the digestive enzymes chymotrypsin, trypsin, and elastase, and proteases involved in blood clotting.
• Serine proteases possess a characteristic "catalytic triad" comprising serine, aspartic acid, and histidine, that together function to activate serine to form a covalent bond with the enzyme substrate, thereby hydrolyzing a peptide bond.
• serine proteases participate in a variety of functions including immunity and inflammation.
• treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
• treatment may be administered after one or more symptoms have developed.
• treatment may be administered in the absence of symptoms.
• treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
• the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of cancer, an autoimmune disorder, a neurodegenerative or neurological disorder, schizophrenia, a bone-related disorder, liver disease, or a cardiac disorder.
• the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
• the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
• dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated.
• the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
• patient means an animal, preferably a mammal, and most preferably a human.
• compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
• the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
• a provided composition is administered to a patient in need thereof once daily. Without wishing to be bound by any particular theory, it is believed that prolonged duration of action of an irreversible inhibitor of HCV NS3 protease is particularly advantageous for once daily administration to a patient in need thereof for the treatment of a disorder associated with HCV NS3 protease.
• a provided composition is administered to a patient in need thereof at least once daily. In other embodiments, a provided composition is administered to a patient in need thereof twice daily, three times daily, or four times daily.
• Compounds of formula I for example, generally provide prolonged duration of action when administered to a patient as compared to a corresponding compound of formula I wherein the R 3 moiety of formula I is instead a non-warhead moiety such as straight alkyl (e.g., unsubstituted alkyl), branched alkyl, cycloalkyl, or alkenyl.
• R 3 moiety of formula I is instead a non-warhead moiety such as straight alkyl (e.g., unsubstituted alkyl), branched alkyl, cycloalkyl, or alkenyl.
• a compound of formula I can provide prolonged duration of action when administered to a patient as compared to a corresponding compound of formula I wherein the R 3 moiety of formula I is instead a non- warhead moiety such as methyl, ethyl, propyl, butyl (e.g., t-butyl), unsubstituted straight or branched alkenyl (e.g. C 1-8 alkenyl), cyclohexyl, or cyclopentyl.
• Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
• the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
• inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzy
• the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
• adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
• injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
• acceptable vehicles and solvents that may be employed are water, Ringer's solution, U. S.
• injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
• a compound of the present invention In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide- polyglycolide.
• the rate of compound release can be controlled.
• biodegradable polymers include poly(orthoesters) and poly(anhydrides).
• Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
• compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
• suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
• Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
• the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol
• Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
• the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
• the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
• the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
• the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
• Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
• the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
• Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
• the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
• Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
• the invention relates to a method of inhibiting serine protease activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
• the invention relates to a method of inhibiting HCV protease, or a mutant thereof, activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
• the invention relates to a method of irreversibly inhibiting HCV protease, or a mutant thereof, activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
• biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
• Inhibition of HCV protease, or a mutant thereof, activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, biological specimen storage, and biological assays.
• Another embodiment of the present invention relates to a method of inhibiting HCV protease, or a mutant thereof, activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.
• the invention relates to a method of inhibiting HCV protease, or a mutant thereof, activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.
• the invention relates to a method of irreversibly inhibiting HCV protease, or a mutant thereof, activity in a patient comprising the step of administering to said patient a compound of the present invention, or a composition comprising said compound.
• the present invention provides a method for treating a disorder mediated by HCV protease, or a mutant thereof, in a patient in need thereof, comprising the step of administering to said patient a compound according to the present invention or pharmaceutically acceptable composition thereof.
• additional therapeutic agents which are normally administered to treat that condition, may be administered in combination with compounds and compositions of this invention.
• a provided compound, or composition thereof is administered in combination with another inhibitor of HCV protease, or a variant thereof. In some embodiments, a provided compound, or composition thereof, is administered in combination with another antiviral agent.
• antiviral agents include, but are not limited to, immunomodulatory agents, such as ⁇ -, ⁇ -, and ⁇ -interferons, pegylated derivatized interferon- ⁇ compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors, e.g.
• BILN 2061 and VX-950 inhibitors of other targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad- spectrum viral inhibitors, such as IMPDH inhibitors (e.g., mycophenolic acid and derivatives thereof); or combinations of any of the above.
• IMPDH inhibitors e.g., mycophenolic acid and derivatives thereof
• a combination of 2 or more antiviral agents may be administered. In certain embodiments, a combination of 3 or more antiviral agents may be administered. In some embodiments, the antiviral agents are selected from ribavirin or interferon. In other embodiments, the antiviral agent is ⁇ -interferon.
• agents the inhibitors of this invention may also be combined with include, without limitation: treatments for Alzheimer's Disease such as Aricept R and Excelon R ; treatments for HIV such as ritonavir; treatments for Parkinson's Disease such as L- DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex ® and Rebif ® ), Copaxone ® , and mitoxantrone; treatments for asthma such as albuterol and Singulair ® ; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-I RA, azathioprine, cyclophosphamide, and s
• Those additional agents may be administered separately from an inventive compound-containing composition, as part of a multiple dosage regimen.
• those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.
• the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention.
• a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
• the present invention provides a single unit dosage form comprising a compound of formula I, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
• compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of an inventive can be administered.
• compositions which comprise an additional therapeutic agent that additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 100 mg/kg body weight/day of the additional therapeutic agent can be administered.
• the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
• the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
• step Ia To a solution of the product of step Ia (0.35 g, 0.66 mmol) in 5 mL of THF/ MeOH (1 :1) was added IN LiOH aqueous solution (2 mL, 2.0 mmol). After stirring at r.t. for 10 hours, the reaction mixture was neutralized with 1.0 N HCl. The organic solvents were evaporated under vacuum, and the remaining aqueous phase was acidified to pH ⁇ 3 using 1.0 N HCl and was extracted with EtOAc. The organic layer was washed with brine, and was dried over anhydrous magnesium sulfate. After removal of solvent, 0.3 g of the title compound was obtained: MS m/z:
• step1b To a solution of the product of step1b (0.30 g, 0.6 mmol) in 10 mL of DCM was added CDI (0.16 g, 1.0 mmol) and the resulting solution was stirred at 4O°C for 1 hour, cyclopropylsulfonamide (0.18 g, 1.5 mmol) and DBU (0.16 g, 1.0 mmol) were added to the reaction mixture. The mixture was stirred at 4O 0 C for additional 10 hours. The solvent was then removed and the residue was diluted with EtOAc and was washed with aqueous NaOAc buffer (pH ⁇ 5, 2x10 mL), NaHCO 3 solution and brine.
• CDI cyclopropylsulfonamide
• DBU DBU
• step Ie The product from step Ic (0.25 g, 0.41 mmol) was dissolved in 4 N HCl in dioxane. The mixture was stirred at r.t. for 1 hour. After removal of solvents, a 10-mL portion of DCM was poured in followed by evaporation to dryness. This process of DCM addition followed by evaporation was repeated four times to give a residue solid which was used directly for the next step: MS m/z: 507.0 (M+H + ). Step Ie: Intermediate Ie
• step 2a The product from step 2a (0.10 g, 0.15 mmol) was dissolved in 2 mL of 4 N HCl in dixoxane and the reaction was stirred for 1 hour at RT. After removal of solvents, a 3-mL portion of DCM was poured in followed by evaporation to dryness. This process of DCM addition followed by evaporation was repeated three times to give the title compound Intermediate 2b as its HCl salt (0.10 g). MS m/z: 564.0 (M+H + ). Step 2c:
• Compound 1-15 was made by following the procedures described in Example 3, using allyl bromide in step 3b in place of methyl iodide.
• Step 8a Intermediate 8a:
• (S)-2-benzyl l-(2,2-dimethylhex-5-enyl) 5-oxopyrrolidine-1,2-dicarboxylate (Intermediate 10-1): At 0 0 C, to a stirring solution of 440 mg of S-Oxo-pyrrolidine ⁇ -carboxylic acid benzyl ester (2 mmol), 300 uL of triethylamine, 300 mg of N,N-dimethylaminopyridine (2.2mmol) in 7 mL of dichloromethane, was added 2 mmol of 4-pentenyl-1-yl chloro formate. The reaction mixture was then warmed to rt, and stirred 24 hr.
• the single-chain proteolytic domain (NS4A 2 i- 32 -GSGS-NS 33 _ 63 i) was cloned into pET-14b (Novagen, Madison, WI) and transformed into DHlOB cells (Invitrogen). The resulting plasmid was transferred into Escherichia coli BL21 (Novagen) for protein expression and purification as described previously (1, 2). Briefly, the cultures were grown at 37 °C in LB medium containing 100 ⁇ g/mL of ampicillin until the optical density at 600 nm (OD600) reached 1.0 and were induced by addition of isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) to 1 mM.
• IPTG isopropyl- ⁇ -D-thiogalactopyranoside
• bacteria were harvested by centrifugation at 6,000 xg for 10 min and resuspended in a lysis buffer containing 50 mM Na 3 PO 4 , pH 8.0, 300 mM NaCl, 5 mM 2-mercaptoethanol, 10% glycerol, 0.5% Igepal CA630, and a protease inhibitor cocktail consisting of 1 mM phenylmethylsulfonyl fluoride, 0.5 ⁇ g/mL leupeptin, pepstatin A, and 2mM benzamidine. Cells were lysed by freezing and thawing, followed by sonication.
• the protein was analyzed by Western blot analysis using monoclonal antibodies against NS3. Proteins were visualized by using a chemiluminescence kit (Roche) with horseradish peroxidase-conjugated goat anti-mouse antibodies (Pierce) as secondary antibodies. The protein was aliquoted and stored at -80 °C. EXAMPLE 12
• mutant DNA fragments of NS4A/NS3 were generated by PCR and cloned into pET expression vector. After transformation into BL21 competent cells, the expression was induced with IPTG for 2 hours. The His-tagged fusion proteins were purified using affinity column followed by size exclusion chromatography.
• Assay buffer 2% CHAPS, 5OmM Tris pH 7.5, 50% glycerol, 2uM M-2235 (Bachem) substrate.
• Assay buffer 2% CHAPS, 5OmM Tris pH 7.5, 50% glycerol, 2uM M-2235 (Bachem) substrate.
• IuI IU
• HCV serine protease
• the enzyme tolerated 1% DMSO and 2% methanol.
• the compounds in pure DMSO were diluted 10 times with 20% methanol (10% DMSO and 20% methanol). This compound solution was added to the reaction (not exceeding 10% of the final reaction volume).
• the final concentration of the organic solvents was: 1% DMSO and 2% methanol.
• HCV RNA replicons The compounds were assayed to evaluate the antiviral activity and cytotoxicity of compounds in vitro using HCV RNA replicons.
• This assay used the cell line ET (luc-ubi- neo/ET), which is a human Huh7 hepatoma cell line that contains an HCV RNA replicon with a stable luciferase (Luc) reporter and three cell culture-adaptive mutations.
• ET luc-ubi- neo/ET
• Luc stable luciferase
• the ET cell line was grown in Dulbecco's modified essential media (DMEM), 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (pen-strep), 1% glutamine, 250 ⁇ g/mL G418 in a 5% CO 2 incubator at 37°C. All cell culture reagents were obtained from Mediatech (Manassas, VA). Cells were trypsinized (1% trypsin:EDTA) and plated out at 5 x 10 3 cells/well in white 96-well assay plates (Costar) dedicated to cell number (cytotoxicity) or antiviral activity assessments.
• DMEM Dulbecco's modified essential media
• FBS fetal bovine serum
• pen-strep penicillin-streptomycin
• glutamine 250 ⁇ g/mL G418
• All cell culture reagents were obtained from Mediatech (Manassas, VA). Cells were trypsinized (1% trypsin:EDTA)
• Drugs were added at six 3 -fold concentrations each and the assay was run in DMEM, 5% FBS, 1% pen-strep, 1% glutamine. Human interferon alpha-2b (PBL Biolabs, New Brunswick, NJ) was included in each run as a positive control compound. Cells were processed 72 hr post drug addition when the cells are still subconfluent. Antiviral activity was measured by analyzing replicon-derived luciferase activity using the Steady-Glo Luciferase Assay System (Promega, Madison, WI) according to manufacturer's instruction. The number of cells in each well was determined by CytoTox-1 reagent (Promega).
• Compound profile was derived by calculating applicable EC 50 (effective concentration inhibiting virus replication by 50%), EC 90 (effective concentration inhibiting virus replication by 90%), IC 50 (concentration decreasing cell viability by 50%) and SI 50 (selective index: EC 50 /IC 50 ) values.
• IC 50 values for selected compounds are set forth in Table 5, below.
• Method B HCV protease assay using FRET methodology
• a quantitative, fluorescence resonance energy transfer (FRET)-based methodology was employed to identify HCV NS3/4A protease inhibitors.
• the assay employed a synthetic FRET peptide, derived from the HCV NS5A/5B cleavage site, with the HCV protease to evaluate the activity of compounds against the protease by monitoring the cleavage activity of the complex.
• a synthetic peptide which encompasses the NS5A-5B junction (NH2- EDVVCCSMSYK-COOH) was labeled with Dabcyl and Edans at N- and C-termini, respectively (Invitrogen, Carlsbad, CA). Fluorescence measurement was used to estimate the IC 50 value of the test compound.
• the two fluorophores form a quenching pair and exhibit FRET within the intact peptide.
• 1OX stocks of NS3/4A protease enzyme from Bioenza (Mountain View, CA) and 1.13X 5-FAM/QXLTM520 FRET peptide substrate from Anaspec (San Jose, CA) were prepared in 50 mM HEPES, pH 7.8, 100 mM NaCl, 5 mM DTT and 20% glycerol. 5 ⁇ L of each enzyme were pre-incubated in a Corning (#3573) 384-well, black, non-treated microtiter plate (Corning, NY) for 30 min at 25 0 C with a 0.5 ⁇ L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO.
• Protease reactions were started with the addition of 45 ⁇ L of the FRET substrate and monitored for 120 minutes at ⁇ e X 487/ ⁇ ⁇ ; m 514 through Quad 4 monochromoters in a Synergy plate reader from BioTek (Winooski, VT).
• progress curves from each well were examined for linear reaction kinetics and fit statistics (R 2 , absolute sum of squares).
• Initial velocity (0 minutes to 30+ minutes) from each reaction was determined from the slope of a plot of relative fluorescence units vs time (minutes) and then plotted against inhibitor concentration to estimate IC50 from log[Inhibitor] vs Response, Variable Slope model in GraphPad Prism from GraphPad Software (San Diego, CA).
• IC 50 values for selected compounds are set forth in Table 5, below.
• Table 5 shows the activity of selected compounds of this invention in the FRET Assay.
• the compound numbers correspond to the compound numbers in Table 3.
• Compounds having an activity designated as "A” provided an IC 50 ⁇ 10 nM; compounds having an activity designated as “B” provided an IC 50 10-100 nM; compounds having an activity designated as “C” provided an IC50 of 100-1000 nM; compounds having an activity designated as “D” provided an IC 50 of 1000-10,000 nM; and compounds having an activity designated as "E” provided an IC 50 >10,000 nM.
• the protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A Ib protease enzyme as follows: 1OX stocks of NS3/4A protease enzyme from Bioenza (Mountain View, CA) and 1.13X 5-FAM/QXLTM520 FRET peptide substrate from Anaspec (San Jose, CA) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol.
• Table 6 shows the activity of selected compounds of this invention in the FRET Assay.
• the compound numbers correspond to the compound numbers in Table 3.
• Compounds having an activity designated as "A” provided an IC 50 ⁇ 10 nM; compounds having an activity designated as “B” provided an IC 50 >10 nM and ⁇ 100 nM; compounds having an activity designated as “C” provided an IC50 >100 nM and ⁇ IOOO nM; compounds having an activity designated as "D” provided an IC 50 >1000 nM and ⁇ 10,000 nM; and compounds having an activity designated as "E” provided an IC50 >10,000 nM.
• HCV wild type or HCV variant C159S Mass spectrometric analysis of HCV wild type or HCV variant C159S in the presence of test compound is performed. 100 pmols of HCV wild type (Bioenza CA) is incubated with test compound for 1 hr and 3 hrs at 10-fold access of test compound to protein. IuI aliquots of the samples (total volume of 4.24ul) are diluted with lOul of 0.1% TFA prior to micro C4 Zip Tipping directly onto the MALDI target using Sinapinic acid as the desorption matrix (10 mg/mL in 0.1%TFA:Acetonitrile 50:50).
• HCV is incubated with test compound for 3 hrs prior to tryptic digestion.
• Iodoacetamide is used as the alkylating agent after compound incubation.
• For tryptic digests a 2 ul aliquot (0.06ug/ul) is diluted with 10 ul of 0.1% TFA prior to micro C18 Zip Tipping directly onto the MALDI target using alpha cyano-4-hydroxy cinnamic acid as the matrix (5 mg/mL in 0.1%TFA:Acetonitrile 50:50).
• the instrument is set in Reflectron mode with a pulsed extraction setting of 1800. Calibration is done using the Laser Biolabs Pep Mix standard (1046.54, 1296.69, 1672.92, 2093.09, 2465.20).
• the peptide is selected using cursors to set ion gate timing and fragmentation occurred at a laser power about 20% higher and He is used as the collision gas for CID.
• Calibration for fragments is done using the P14R fragmentation calibration for the Curved field Reflectron.
• NS3/4A wild type (wt) was incubated for 1 hr at a 1OX fold access of test compound to protein.
• TFA:Acetonitrile 50:50 TFA:Acetonitrile 50:50.
• the instrument was set in linear mode using a pulsed extraction setting of 24,500 and apomyoglobin as the standard to calibrate the instrument.
• HCV Mutants (A156S), (R155K), (D168A), (A156T), and (D168V) were incubated for 3 hrs at a 1OX fold access of test compound to protein. 2 ul aliquots of the samples were diluted with lOul of 0.1% TFA prior to micro C4 Zip Tipping directly onto the MALDI target using Sinapinic acid as the desorption matrix (10 mg/ml in 0.1% TFA:Acetonitrile 50:50). For intact protein mass measurement the instrument was set in linear mode using a pulsed extraction setting of 24,500 and apomyoglobin as the standard to calibrate the instrument.
• Huh-luc/neo-ET, Huh7-Lunet were obtained from ReBLikon Gmbh (Heidelberg, Germany). Cells were grown in Dulbecco modified Eagle medium (DMEM; Invitrogen) supplemented with 2 mM L-glutamine, nonessential amino acids, 100 U of penicillin/ml, 100 ⁇ g of streptomycin/mL, and 10% fetal bovine serum. G418 (Geneticin; Invitrogen) was added at a final concentration of 400ug//mL. Huh7-Lunet were grown in the absence of G418.
• DMEM Dulbecco modified Eagle medium
• G418 Geneticin; Invitrogen
• Constructs containing clinically relevant mutations were generated by performing site-directed mutagenesis on the pFK-I389-luc-ubi-neo-NS3-3'ET plasmid (ReBLikon Gmbh (Heidelberg, Germany)), using the QuickChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to manufacturer's directions and with the primers described in Table 7, below.
• In vitro transcription reactions contained 80 mM HEPES (pH 7.5), 12 mM MgCl 2 , 2 mM spermidine, 40 mM dithiothreitol, a 3.125 mM concentration of each nucleoside triphosphate, 1 U of RNasin. 5 ug of restricted plasmid DNA and 80 U of T7 RNA polymerase (Promega) was used. After 2 h at 37 °C, an additional 40 U of T7 polymerase was added, and the reaction was incubated for another 2 h.
• Huh-7-Luc-Neo-ET cells were plated in Replicon Assay Medium (RPMI supplemented with 5% FBS, IX non-essential amino acids and pen/strep) at a density of 1 x 10 cells/well in 12 well plates. Eight hours later the media was removed and replaced with 1 ml media containing test compound (5 wells per compound) and 0.02% DMSO and the cells were returned to the incubator overnight. Sixteen hours later 1 well from each compound and 1 untreated well were washed with PBS, then lysed and scraped into 30 ul of Cell Extraction Buffer (Biosource, Camarillo, CA) plus Complete Protease Inhibitor (Roche, Indianapolis, IN).
• Figure 8 depicts that the NS3 internal self-cleavage products are inhibited by treatement of replicon cells with Compound 1-47 for 16 hours.
• Figure 9 depicts an irreversible covalent inhibitor (compound 1-11) of NS3 protease demonstrate prolonged inhibition of NS3 protease activity in the wild-type replicon cells, as measured by self-cleavage, after the compounds are removed. The compound was incubated with replicon cells for 16 hours and then removed (time 0). Even up to 48 hours after removal of a covalent irreversible NS3 inhibitor, NS3 self-cleaving activity is inhibited by at least 50%, whereas a reversible drug, VX-950, shows virtually complete return of activity in as little as 4 hours after drug removal.
• Figure 10 depicts an irreversible covalent inhibitor (compound 1-25) of NS3 protease demonstrate prolonged inhibition of NS3 protease activity in the wild-type replicon cells, as measured by self-cleavage, after the compounds are removed. The compound was incubated with replicon cells for 16 hours and then removed (time 0). Even up to 48 hours after removal of a covalent irreversible NS3 inhibitor, NS3 self-cleaving activity is inhibited by at least 40%, whereas a reversible drug, VX-950, shows virtually complete return of activity in as little as 8 hours after drug removal.
• compound 1-25 an irreversible covalent inhibitor
• the compounds were assayed to evaluate the antiviral activity and cytotoxicity of compounds using replicon-derived luciferase activity.
• This assay used the cell line ET (luc-ubi- neo/ET), which is a human Huh7 hepatoma cell line that contains an HCV RNA replicon with a stable luciferase (Luc) reporter and cell culture-adaptive mutations.
• ET luc-ubi- neo/ET
• Luc stable luciferase
• the ET cell line was grown in a 5% CO 2 incubator at 37 °C in Dulbecco's modified essential media (DMEM) supplemented with 2 mM L-glutamine, nonessential amino acids, 100 U of penicillin/ml, 100 ⁇ g of streptomycin/mL, and 10% fetal bovine serum.
• DMEM Dulbecco's modified essential media
• nonessential amino acids 100 U of penicillin/ml
• 100 ⁇ g of streptomycin/mL 100 ⁇ g of streptomycin/mL
• 10% fetal bovine serum fetal bovine serum.
• G418 Geneticin; Invitrogen
• Antiviral activity was measured by analyzing replicon-derived luciferase activity using the Steady-Glo Luciferase Assay System (Promega, Madison, WI) according to manufacturer's instruction. The number of cells in each well was determined by Cell Titer Blue Assay (Promega). Compound profile was derived by calculating applicable EC 50 (effective concentration inhibiting virus replication by 50%), EC 90 (effective concentration inhibiting virus replication by 90%), IC 50 (concentration decreasing cell viability by 50%) and SI 50 (selective index: EC50/IC50) values.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Virology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Crystallography & Structural Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (12)

Applications Claiming Priority (8)

Publications (2)

Family

ID=40801571

Family Applications (1)

Country Status (14)

Cited By (42)

Families Citing this family (5)

Citations (5)

Family Cites Families (96)

• 2008
  • 2008-12-19 CA CA2710144A patent/CA2710144A1/en not_active Abandoned
  • 2008-12-19 US US12/339,770 patent/US8778877B2/en not_active Expired - Fee Related
  • 2008-12-19 CN CN200880127242.XA patent/CN101951769B/zh not_active Expired - Fee Related
  • 2008-12-19 NZ NZ586232A patent/NZ586232A/xx not_active IP Right Cessation
  • 2008-12-19 RU RU2010125120/04A patent/RU2523790C2/ru not_active IP Right Cessation
  • 2008-12-19 CN CN201410718581.2A patent/CN104557880A/zh active Pending
  • 2008-12-19 TW TW097149686A patent/TWI487522B/zh not_active IP Right Cessation
  • 2008-12-19 AU AU2008340261A patent/AU2008340261C1/en not_active Ceased
  • 2008-12-19 KR KR1020157026393A patent/KR20150113217A/ko not_active Abandoned
  • 2008-12-19 TW TW104107418A patent/TW201546079A/zh unknown
  • 2008-12-19 KR KR1020107015692A patent/KR20100131970A/ko not_active Abandoned
  • 2008-12-19 MX MX2010006738A patent/MX2010006738A/es active IP Right Grant
  • 2008-12-19 JP JP2010539887A patent/JP5755450B2/ja not_active Expired - Fee Related
  • 2008-12-19 EP EP08864666A patent/EP2237666A4/en not_active Withdrawn
  • 2008-12-19 WO PCT/US2008/087736 patent/WO2009082701A1/en not_active Ceased
• 2010
  • 2010-06-18 ZA ZA2010/04338A patent/ZA201004338B/en unknown
• 2014
  • 2014-07-14 US US14/331,161 patent/US9676785B2/en not_active Expired - Fee Related
• 2015
  • 2015-02-02 JP JP2015018258A patent/JP2015110627A/ja not_active Ceased
  • 2015-10-29 HK HK15110729.0A patent/HK1210142A1/xx unknown

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events